Y Intercept Hong Kong Ltd Sells 107,806 Shares of Bausch Health Cos Inc. $BHC

Y Intercept Hong Kong Ltd reduced its position in Bausch Health Cos Inc. (NYSE:BHC) by 50.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,425 shares of the company’s stock after selling 107,806 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Bausch Health Cos were worth $564,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Leonteq Securities AG boosted its position in shares of Bausch Health Cos by 150.1% during the first quarter. Leonteq Securities AG now owns 49,951 shares of the company’s stock valued at $270,000 after buying an additional 29,975 shares during the period. MQS Management LLC bought a new position in shares of Bausch Health Cos during the first quarter valued at approximately $94,000. Pictet Asset Management Holding SA raised its holdings in shares of Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock worth $292,000 after buying an additional 2,114 shares during the period. Ritholtz Wealth Management raised its holdings in shares of Bausch Health Cos by 178.8% in the first quarter. Ritholtz Wealth Management now owns 222,459 shares of the company’s stock worth $1,201,000 after buying an additional 142,663 shares during the period. Finally, Viewpoint Capital Management LLC bought a new stake in shares of Bausch Health Cos during the 1st quarter worth approximately $97,000. Institutional investors own 78.65% of the company’s stock.

Insider Buying and Selling at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the transaction, the director owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This represents a 33.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada decreased their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Stock Performance

Bausch Health Cos stock opened at $4.86 on Tuesday. The company has a 50 day moving average price of $5.15 and a 200-day moving average price of $5.70. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. Bausch Health Cos Inc. has a fifty-two week low of $4.57 and a fifty-two week high of $8.69. The company has a market capitalization of $1.82 billion, a PE ratio of -1.50 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%. As a group, equities analysts forecast that Bausch Health Cos Inc. will post 4.05 earnings per share for the current year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.